Maximum androgen blockade
Maximum or maximal androgen blockade (MAB) or complete or combined androgen blockade (CAB) is a medical treatment involving the combination of both androgen receptor (AR) antagonism and inhibition or suppression of androgen production to attain maximal effectiveness in androgen deprivation therapy (ADT).[1] An example of MAB is the combination of bicalutamide, an AR antagonist, with a gonadotropin-releasing hormone (GnRH) analogue such as leuprorelin or cetrorelix.[1] MAB was developed for and is employed in the treatment of prostate cancer.[1]
Triple androgen blockade (TrAB) is a method of ADT in which a 5α-reductase inhibitor such as finasteride or dutasteride is added to CAB.[2][3]
References
- 1 2 3 "Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials". The Lancet. 355 (9214): 1491–1498. 2000. ISSN 0140-6736. doi:10.1016/S0140-6736(00)02163-2.
- ↑ Hellerstedt, Beth A; Pienta, Kenneth J (2003). "The truth is out there: an overall perspective on androgen deprivation". Urologic Oncology: Seminars and Original Investigations. 21 (4): 272–281. ISSN 1078-1439. doi:10.1016/S1078-1439(03)00046-2.
- ↑ Leibowitz RL, Tucker SJ (2001). "Treatment of localized prostate cancer with intermittent triple androgen blockade: preliminary results in 110 consecutive patients". The Oncologist. 6 (2): 177–82. PMID 11306729. doi:10.1634/theoncologist.6-2-177.
| AR |
| ||||||
|---|---|---|---|---|---|---|---|
| GPRC6A |
| ||||||
| |||||||
This article is issued from
Wikipedia.
The text is licensed under Creative Commons - Attribution - Sharealike.
Additional terms may apply for the media files.